Adverse events192

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 192

Type	Event	Organ system	Group	Affected	At risk	Events
other	Dermatitis atopic	Skin and subcutaneous tissue disorders	Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg	34	519	42
other	Dermatitis atopic	Skin and subcutaneous tissue disorders	Initial Treatment Period (Baseline - Week 16 Predose): Placebo	15	263	15
other	Dermatitis atopic	Skin and subcutaneous tissue disorders	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q4W	6	79	7
other	Dermatitis atopic	Skin and subcutaneous tissue disorders	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q8W	3	77	4
other	Dermatitis atopic	Skin and subcutaneous tissue disorders	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W	6	77	7
other	Dermatitis atopic	Skin and subcutaneous tissue disorders	Maintenance Period (Week 16- Week 48): Placebo Q4W Re-assigned to Placebo Q4W	5	84	5
other	Nasopharyngitis	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg	19	519	24
other	Nasopharyngitis	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Placebo	12	263	13
other	Nasopharyngitis	Infections and infestations	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q4W	7	79	12
other	Nasopharyngitis	Infections and infestations	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q8W	3	77	6
other	Nasopharyngitis	Infections and infestations	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W	5	77	6
other	Nasopharyngitis	Infections and infestations	Maintenance Period (Week 16- Week 48): Placebo Q4W Re-assigned to Placebo Q4W	6	84	8
other	COVID-19	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg	14	519	14
other	COVID-19	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Placebo	8	263	8
other	COVID-19	Infections and infestations	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q4W	3	79	3
other	COVID-19	Infections and infestations	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q8W	4	77	4
other	COVID-19	Infections and infestations	Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W	13	77	13
other	COVID-19	Infections and infestations	Maintenance Period (Week 16- Week 48): Placebo Q4W Re-assigned to Placebo Q4W	6	84	6
other	Upper respiratory tract infection	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg	6	519	6
other	Upper respiratory tract infection	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Placebo	5	263	5

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03989349/events

API reference For AI assistants

Adverse events192

Sources 3

Read this list from software.